Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

• Status: Recruiting
• Trial end date: 2025-01-01

Summary

Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option

• Phase: Phase 3

Details

• Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Collaborator: GlaxoSmithKline
• Treatments: Bevacizumab; Doxorubicin; Gemcitabine; Liposomal doxorubicin; Niraparib; Paclitaxel; Topotecan